 Greta Wilkening
Concepts (195)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lennox Gastaut Syndrome | 3 | 2022 | 17 | 1.090 |
Why?
| | Brain Diseases | 3 | 2022 | 141 | 0.890 |
Why?
| | Neuropsychology | 3 | 2024 | 37 | 0.880 |
Why?
| | Memory Disorders | 2 | 2012 | 164 | 0.680 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 2 | 2012 | 77 | 0.670 |
Why?
| | Central Nervous System Neoplasms | 2 | 2012 | 156 | 0.630 |
Why?
| | Cognition | 10 | 2024 | 1153 | 0.550 |
Why?
| | Brain Neoplasms | 4 | 2022 | 1238 | 0.530 |
Why?
| | Medical Oncology | 1 | 2017 | 289 | 0.440 |
Why?
| | Neuropsychological Tests | 8 | 2024 | 1023 | 0.440 |
Why?
| | Phenylketonurias | 2 | 2024 | 15 | 0.430 |
Why?
| | Urea Cycle Disorders, Inborn | 2 | 2024 | 23 | 0.430 |
Why?
| | Hyperammonemia | 2 | 2024 | 16 | 0.430 |
Why?
| | Pediatrics | 2 | 2024 | 1101 | 0.420 |
Why?
| | Mass Screening | 1 | 2022 | 1287 | 0.420 |
Why?
| | Nursing Assessment | 1 | 2012 | 59 | 0.380 |
Why?
| | Child | 30 | 2024 | 21935 | 0.370 |
Why?
| | Prenatal Exposure Delayed Effects | 3 | 2024 | 605 | 0.360 |
Why?
| | Developmental Disabilities | 3 | 2020 | 263 | 0.330 |
Why?
| | Hemophilia A | 2 | 2024 | 139 | 0.320 |
Why?
| | Adolescent | 20 | 2025 | 21513 | 0.300 |
Why?
| | Diabetes Mellitus, Type 2 | 4 | 2025 | 2531 | 0.300 |
Why?
| | Epilepsies, Myoclonic | 2 | 2020 | 51 | 0.290 |
Why?
| | Child, Preschool | 18 | 2024 | 11074 | 0.280 |
Why?
| | Neurodevelopmental Disorders | 2 | 2020 | 181 | 0.270 |
Why?
| | Child Development | 3 | 2019 | 475 | 0.270 |
Why?
| | Cross-Sectional Studies | 6 | 2025 | 5472 | 0.260 |
Why?
| | Epilepsy | 2 | 2023 | 333 | 0.250 |
Why?
| | Electroencephalography | 3 | 2024 | 423 | 0.250 |
Why?
| | Brain | 5 | 2025 | 2668 | 0.230 |
Why?
| | Seizures | 3 | 2024 | 426 | 0.220 |
Why?
| | Ammonia | 1 | 2024 | 62 | 0.220 |
Why?
| | Survivors | 4 | 2017 | 493 | 0.210 |
Why?
| | Oxytocin | 1 | 2024 | 51 | 0.210 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 2 | 2024 | 413 | 0.200 |
Why?
| | Humans | 43 | 2025 | 137585 | 0.200 |
Why?
| | Clinical Trials as Topic | 2 | 2024 | 1050 | 0.190 |
Why?
| | Infant | 10 | 2024 | 9465 | 0.180 |
Why?
| | Amnesia | 2 | 2012 | 43 | 0.180 |
Why?
| | Rare Diseases | 1 | 2022 | 104 | 0.180 |
Why?
| | Hallucinogens | 1 | 2023 | 105 | 0.170 |
Why?
| | NAV1.2 Voltage-Gated Sodium Channel | 1 | 2020 | 8 | 0.170 |
Why?
| | Cannabidiol | 1 | 2023 | 119 | 0.170 |
Why?
| | Cannabinoids | 1 | 2023 | 161 | 0.170 |
Why?
| | Shab Potassium Channels | 1 | 2020 | 18 | 0.170 |
Why?
| | Brain Damage, Chronic | 2 | 1999 | 18 | 0.170 |
Why?
| | KCNQ2 Potassium Channel | 1 | 2020 | 10 | 0.170 |
Why?
| | Young Adult | 8 | 2025 | 13209 | 0.160 |
Why?
| | Status Epilepticus | 1 | 2020 | 50 | 0.160 |
Why?
| | Epileptic Syndromes | 1 | 2020 | 84 | 0.160 |
Why?
| | Self-Injurious Behavior | 1 | 2021 | 130 | 0.160 |
Why?
| | Adaptation, Psychological | 2 | 2024 | 655 | 0.160 |
Why?
| | Mothers | 2 | 2023 | 754 | 0.160 |
Why?
| | Incidence | 4 | 2019 | 2804 | 0.150 |
Why?
| | Communication | 2 | 2022 | 879 | 0.150 |
Why?
| | Autism Spectrum Disorder | 1 | 2024 | 395 | 0.150 |
Why?
| | Autistic Disorder | 1 | 2021 | 204 | 0.150 |
Why?
| | Female | 27 | 2025 | 73304 | 0.150 |
Why?
| | Frontal Lobe | 1 | 1999 | 149 | 0.140 |
Why?
| | Male | 24 | 2025 | 67762 | 0.140 |
Why?
| | Maternal Exposure | 1 | 2019 | 190 | 0.140 |
Why?
| | Sleep | 3 | 2020 | 755 | 0.140 |
Why?
| | Brain Waves | 1 | 2017 | 33 | 0.140 |
Why?
| | Tobacco Smoke Pollution | 1 | 2019 | 261 | 0.130 |
Why?
| | Benzodiazepines | 1 | 2017 | 155 | 0.130 |
Why?
| | Obesity | 4 | 2025 | 2992 | 0.130 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2023 | 3715 | 0.130 |
Why?
| | Liver Transplantation | 1 | 2023 | 871 | 0.120 |
Why?
| | Cannabis | 1 | 2023 | 494 | 0.120 |
Why?
| | Overweight | 1 | 2020 | 558 | 0.120 |
Why?
| | Body Mass Index | 1 | 2024 | 2389 | 0.120 |
Why?
| | Magnetic Resonance Imaging | 3 | 2025 | 3566 | 0.120 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2012 | 82 | 0.120 |
Why?
| | Stress, Psychological | 1 | 2023 | 1100 | 0.110 |
Why?
| | Diabetes Mellitus | 1 | 2023 | 1040 | 0.110 |
Why?
| | Perception | 1 | 2017 | 359 | 0.110 |
Why?
| | Infant, Newborn | 3 | 2022 | 6079 | 0.110 |
Why?
| | Biomarkers | 2 | 2019 | 4149 | 0.110 |
Why?
| | Adult | 10 | 2025 | 37929 | 0.110 |
Why?
| | Surveys and Questionnaires | 3 | 2022 | 5778 | 0.100 |
Why?
| | Cerebral Arterial Diseases | 1 | 2012 | 47 | 0.100 |
Why?
| | Retrospective Studies | 8 | 2024 | 15657 | 0.100 |
Why?
| | Parents | 2 | 2021 | 1347 | 0.100 |
Why?
| | Cohort Studies | 5 | 2024 | 5742 | 0.100 |
Why?
| | Pregnancy | 5 | 2024 | 6763 | 0.100 |
Why?
| | Germinoma | 1 | 2012 | 10 | 0.100 |
Why?
| | Whole-Body Irradiation | 1 | 2012 | 78 | 0.090 |
Why?
| | Oncology Nursing | 1 | 2012 | 22 | 0.090 |
Why?
| | Cerebral Ventricles | 1 | 2012 | 52 | 0.090 |
Why?
| | Pediatric Nursing | 1 | 2012 | 42 | 0.090 |
Why?
| | Radiotherapy, Conformal | 1 | 2012 | 70 | 0.090 |
Why?
| | Smoking | 1 | 2019 | 1627 | 0.090 |
Why?
| | Temporal Lobe | 1 | 2012 | 91 | 0.090 |
Why?
| | Aptitude Tests | 1 | 2011 | 4 | 0.090 |
Why?
| | Intelligence | 1 | 2012 | 123 | 0.090 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2012 | 142 | 0.090 |
Why?
| | Blood Coagulation Disorders | 1 | 2012 | 173 | 0.090 |
Why?
| | Fibrinolytic Agents | 1 | 2012 | 270 | 0.080 |
Why?
| | Thrombophilia | 1 | 2009 | 83 | 0.080 |
Why?
| | Blood Glucose | 1 | 2019 | 2186 | 0.080 |
Why?
| | Insulin | 1 | 2019 | 2409 | 0.070 |
Why?
| | Cognition Disorders | 3 | 2019 | 496 | 0.070 |
Why?
| | Age of Onset | 2 | 2025 | 518 | 0.070 |
Why?
| | Prospective Studies | 4 | 2024 | 7604 | 0.070 |
Why?
| | Longitudinal Studies | 3 | 2024 | 2844 | 0.070 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2012 | 622 | 0.060 |
Why?
| | Short Bowel Syndrome | 1 | 2006 | 26 | 0.060 |
Why?
| | Nutritional Support | 1 | 2006 | 34 | 0.060 |
Why?
| | Brain Ischemia | 1 | 2009 | 338 | 0.060 |
Why?
| | Colorado | 4 | 2019 | 4565 | 0.060 |
Why?
| | Neoplasms | 2 | 2012 | 2671 | 0.060 |
Why?
| | Gray Matter | 1 | 2025 | 80 | 0.060 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2023 | 547 | 0.050 |
Why?
| | Stroke | 1 | 2012 | 1120 | 0.050 |
Why?
| | Hemophilia B | 1 | 2024 | 61 | 0.050 |
Why?
| | Intelligence Tests | 1 | 2023 | 57 | 0.050 |
Why?
| | Risk Assessment | 1 | 2012 | 3457 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 310 | 0.050 |
Why?
| | Diabetic Neuropathies | 1 | 2023 | 94 | 0.050 |
Why?
| | Family Characteristics | 1 | 2023 | 191 | 0.050 |
Why?
| | Diabetes Complications | 1 | 2023 | 227 | 0.040 |
Why?
| | Treatment Outcome | 5 | 2023 | 10811 | 0.040 |
Why?
| | Maternal Inheritance | 1 | 2020 | 16 | 0.040 |
Why?
| | Checklist | 1 | 2021 | 93 | 0.040 |
Why?
| | Language Development | 1 | 2020 | 61 | 0.040 |
Why?
| | Motor Skills | 1 | 2020 | 97 | 0.040 |
Why?
| | Wechsler Scales | 1 | 1999 | 54 | 0.040 |
Why?
| | Executive Function | 1 | 2024 | 451 | 0.040 |
Why?
| | Patient Care Team | 1 | 2024 | 631 | 0.040 |
Why?
| | Referral and Consultation | 1 | 2024 | 786 | 0.040 |
Why?
| | Inflammation | 1 | 2009 | 2837 | 0.040 |
Why?
| | Cognitive Dysfunction | 1 | 2023 | 383 | 0.040 |
Why?
| | Psychological Tests | 3 | 1983 | 140 | 0.030 |
Why?
| | NAV1.1 Voltage-Gated Sodium Channel | 1 | 2017 | 17 | 0.030 |
Why?
| | Fasting | 1 | 2019 | 281 | 0.030 |
Why?
| | Behavioral Symptoms | 1 | 1997 | 42 | 0.030 |
Why?
| | Psychomotor Performance | 1 | 2019 | 309 | 0.030 |
Why?
| | Regression Analysis | 1 | 2019 | 1024 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 1587 | 0.030 |
Why?
| | Brain Mapping | 1 | 1999 | 503 | 0.030 |
Why?
| | Risk Factors | 3 | 2019 | 10388 | 0.030 |
Why?
| | Craniopharyngioma | 1 | 1997 | 74 | 0.030 |
Why?
| | Language | 1 | 2019 | 292 | 0.030 |
Why?
| | Child Behavior Disorders | 1 | 1997 | 144 | 0.030 |
Why?
| | Homeostasis | 1 | 2019 | 621 | 0.030 |
Why?
| | Health Surveys | 1 | 2017 | 514 | 0.030 |
Why?
| | Pituitary Neoplasms | 1 | 1997 | 190 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2017 | 5131 | 0.030 |
Why?
| | Time Factors | 3 | 2012 | 6828 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 1999 | 1946 | 0.030 |
Why?
| | Nervous System Diseases | 1 | 2017 | 266 | 0.030 |
Why?
| | Health Status | 1 | 1999 | 792 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3284 | 0.030 |
Why?
| | Prognosis | 2 | 2012 | 4030 | 0.020 |
Why?
| | Organs at Risk | 1 | 2012 | 32 | 0.020 |
Why?
| | Neurocognitive Disorders | 2 | 1982 | 26 | 0.020 |
Why?
| | Comorbidity | 1 | 2017 | 1622 | 0.020 |
Why?
| | Organ Sparing Treatments | 1 | 2012 | 34 | 0.020 |
Why?
| | Radiotherapy Dosage | 1 | 2012 | 268 | 0.020 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2012 | 130 | 0.020 |
Why?
| | Quality of Life | 1 | 2023 | 2892 | 0.020 |
Why?
| | Tumor Burden | 1 | 2012 | 309 | 0.020 |
Why?
| | Age Factors | 2 | 2012 | 3295 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2019 | 1208 | 0.020 |
Why?
| | Radiography | 1 | 2012 | 822 | 0.020 |
Why?
| | Recurrence | 1 | 2012 | 1060 | 0.020 |
Why?
| | Factor VIII | 1 | 2009 | 98 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2009 | 410 | 0.020 |
Why?
| | Cisapride | 1 | 2006 | 5 | 0.020 |
Why?
| | Mutation | 1 | 2017 | 3958 | 0.020 |
Why?
| | Gastrointestinal Agents | 1 | 2006 | 65 | 0.020 |
Why?
| | Counseling | 1 | 1989 | 391 | 0.010 |
Why?
| | Postoperative Complications | 1 | 1997 | 2654 | 0.010 |
Why?
| | Dysarthria | 1 | 1984 | 10 | 0.010 |
Why?
| | Speech Disorders | 1 | 1984 | 31 | 0.010 |
Why?
| | Infant, Newborn, Diseases | 1 | 2006 | 113 | 0.010 |
Why?
| | Aluminum | 1 | 1984 | 42 | 0.010 |
Why?
| | Personality Disorders | 1 | 1984 | 75 | 0.010 |
Why?
| | Neurologic Examination | 1 | 1983 | 110 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 2 | 1984 | 2691 | 0.010 |
Why?
| | Reference Values | 1 | 1983 | 816 | 0.010 |
Why?
| | Antipsychotic Agents | 1 | 1983 | 194 | 0.010 |
Why?
| | Intellectual Disability | 1 | 1981 | 165 | 0.010 |
Why?
| | Schizophrenia | 1 | 1983 | 439 | 0.010 |
Why?
| | Health Status Indicators | 1 | 1999 | 171 | 0.010 |
Why?
| | Achievement | 1 | 1997 | 58 | 0.010 |
Why?
| | Social Behavior | 1 | 1997 | 287 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 1997 | 2828 | 0.000 |
Why?
| | Tremor | 1 | 1984 | 65 | 0.000 |
Why?
| | Syndrome | 1 | 1984 | 358 | 0.000 |
Why?
| | Phenothiazines | 1 | 1983 | 8 | 0.000 |
Why?
| | Schizophrenic Psychology | 1 | 1983 | 94 | 0.000 |
Why?
| | Aphasia, Wernicke | 1 | 1982 | 2 | 0.000 |
Why?
| | Middle Aged | 1 | 1983 | 33479 | 0.000 |
Why?
| | Kidney Failure, Chronic | 1 | 1984 | 570 | 0.000 |
Why?
|
|
Wilkening's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|